Inequalities in the omission of axillary dissection in sentinel lymph node positive patients in the Netherlands: Innovative hospitals are early adopters of a de‐escalating approach-Reference-Cited by-同舟云学术

Inequalities in the omission of axillary dissection in sentinel lymph node positive patients in the Netherlands: Innovative hospitals are early adopters of a de‐escalating approach

Published:2022-12-27 Issue:7 Volume:152 Page:1378-1387
ISSN:0020-7136
Container-title:International Journal of Cancer
language:en
Short-container-title:Intl Journal of Cancer

Author:

van Steenhoven Julia E. C.¹²,van Maaren Marissa C.³⁴,Verreck Eline E. F.¹,Schipper Robert J.⁵,Nieuwenhuijzen Grard A. P.⁵,Kuijer Anne⁶⁷^ORCID,Siesling Sabine³⁴,van Dalen Thijs¹

Affiliation:

1. Department of Surgery Erasmus MC Rotterdam The Netherlands

2. Department of Pathology University Medical Center Utrecht Utrecht The Netherlands

3. Department of Research and Development Netherlands Comprehensive Cancer Organisation Utrecht The Netherlands

4. Department of Health Technology and Services Research, Technical Medical Centre University of Twente Enschede The Netherlands

5. Department of Surgery Catharina Hospital Eindhoven Eindhoven The Netherlands

6. Department of Surgery St. Antonius Hospital Nieuwegein The Netherlands

7. Department of Surgery University Medical Center Utrecht Utrecht The Netherlands

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ijc.34400

Reference26 articles.

1. Long-Term Results of Hypofractionated Radiation Therapy for Breast Cancer

2. Axillary Dissection vs No Axillary Dissection in Women With Invasive Breast Cancer and Sentinel Node Metastasis

3. Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis

4. Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23–01): a phase 3 randomised controlled trial

5. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial